tert-butyl N-[2-methyl-1-[[(3S,6S)-6-[[(1R)-1-[3-methyl-5-(trifluoromethyl)phenyl]ethoxy]methyl]-6-phenylpiperidin-3-yl]amino]-1-oxopropan-2-yl]carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl N-[2-methyl-1-[[(3S,6S)-6-[[(1R)-1-[3-methyl-5-(trifluoromethyl)phenyl]ethoxy]methyl]-6-phenylpiperidin-3-yl]amino]-1-oxopropan-2-yl]carbamate
• 化学式: C₃₁H₄₂F₃N₃O₄
• 分子量: 577.7
• InChiKey: OVDSUKXNLQVTQI-WKJRGHSNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  88.7
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• NK1 ANTAGONISTS
  申请人：OPKO Health, Inc.

  公开号：US20140296196A1

  公开（公告）日：2014-10-02

  A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK 1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
• NK 1 ANTAGONISTS
  申请人：OPKO Health, Inc.

  公开号：US20170029403A1

  公开（公告）日：2017-02-02

  A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK 1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
• US8754216B2
  申请人：——

  公开号：US8754216B2

  公开（公告）日：2014-06-17
• US9469629B2
  申请人：——

  公开号：US9469629B2

  公开（公告）日：2016-10-18
• US9969711B2
  申请人：——

  公开号：US9969711B2

  公开（公告）日：2018-05-15